Incidence, risk factors, and outcomes associated with cytomegalovirus disease in small bowel transplant recipients

Pediatric Transplantation

Volumn 16, Issue 3, 2012, Pages 294-301

  Florescu, D F ^a   Langnas, A N ^b   Grant, W ^b   Mercer, D F ^b   Botha, J ^b   Qiu, F ^c   Shafer, L ^a   Kalil, A C ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Transplant Division   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

cytomegalovirus; disease; infection; intestinal transplantation; pediatric; small bowel transplantation

Indexed keywords

BASILIXIMAB; CYTOMEGALOVIRUS ANTIBODY; FOSCARNET; GANCICLOVIR; VALGANCICLOVIR;

ADOLESCENT; ADVERSE OUTCOME; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DEATH; DESCRIPTIVE RESEARCH; ENTERITIS; FEMALE; GRAFT RECIPIENT; HUMAN; INCIDENCE; INFANT; KAPLAN MEIER METHOD; MALE; MEDICAL RECORD REVIEW; POSTOPERATIVE COMPLICATION; PRESCHOOL CHILD; REGRESSION ANALYSIS; RISK; RISK FACTOR; SCHOOL CHILD; SMALL INTESTINE; TISSUE TRANSPLANTATION; VIREMIA;

CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFANT; INTESTINES; MALE; MODELS, STATISTICAL; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84859716662     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2011.01628.x     Document Type: Article

References (44)

1. Florescu DF, Islam KM, Sudan D, et al., Outcome in Pediatric Small Bowel Transplantation. 27th European Society of Pediatric Infectious Diseases Meeting (Poster 485); June 9-13, 2009. Belgium: Brussels, 2009.
2. Bueno J, Green M, Kocoshis S, et al., Cytomegalovirus infection after intestinal transplantation in children. Clin Infect Dis 1997: 25: 1078-1083.
3. Abu-Elmagd KM, Costa G, Bond GJ, et al., Five hundred intestinal and multivisceral transplantations at a single center: Major advances with new challenges. Ann Surg 2009: Oct; 250 (4): 567-81.
4. Humar A, Snydman D, AST I nfectious D iseases C ommunity of P ractice. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009: 9 (Suppl. 4): S78-S86.
5. Moellering RC Jr,. Emergence of enterococcus as a significant pathogen. Clin Infect Dis 1992: 14: 1173-1176.
6. Ljungman P, Griffiths P, Paya C,. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002: 34: 1094-1097.
7. Kalil AC, Sun J, Florescu DF,. Induction Immunosupression: What is the Difference in the Risk of Serious Infections Between Interleukin-2RA and Polyclonal Antibodies? (Abstract 317). American Transplant Congress '09; May 30-June 3, 2009; Boston, MA.
8. Falagas ME, Snydman DR, Griffith J, Werner BG, Freeman R, Rohrer R,. Clinical and epidemiological predictors of recurrent cytomegalovirus disease in orthotopic liver transplant recipients. Boston center for liver transplantation CMVIG study group. Clin Infect Dis 1997: 25: 314-317.
9. Sia IG, Wilson JA, Groettum CM, Espy MJ, Smith TF, Paya CV,. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 2000: 181: 717-720.
10. Turgeon N, Fishman JA, Doran M, et al., Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: Effect of oral ganciclovir. Transpl Infect Dis 2000: 2: 2-10.
11. Humar A, Kumar D, Boivin G, Caliendo AM,. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002: 186: 829-833.
12. Levitsky J, Freifeld AG, Puumala S, et al., Cytomegalovirus viremia in solid organ transplantation: Does the initial viral load correlate with risk factors and outcomes? Clin Transplant 2008: 22: 222-228.
13. Shanahan A, Malani PN, Kaul DR,. Relapsing cytomegalovirus infection in solid organ transplant recipients. Transpl Infect Dis 2009: 11: 513-518.
14. Pinchoff RJ, Kaufman SS, Magid MS, et al., Adenovirus infection in pediatric small bowel transplantation recipients. Transplantation 2003: 76: 183-189.
15. Mclaughlin GE, Delis S, Kashimawo L, et al., Adenovirus infection in pediatric liver and intestinal transplant recipients: Utility of DNA detection by PCR. Am J Transplant 2003: 3: 224-228.
16. Ziring D, Tran R, Edelstein S, et al., Infectious enteritis after intestinal transplantation: Incidence, timing, and outcome. Transplantation 2005: 79: 702-709.
17. Florescu DF, Islam MK, Mercer DF, et al., Adenovirus infections in pediatric small bowel transplant recipients. Transplantation 2010: 90: 198-204.
18. Paya CV, Razonable RR,. Cytomegalovirus infections after solid organ transplantation. In:, Bowden RA, Ljungman P, Paya CV, eds. Transplant Infections, 2nd edn. Philadelphia: Lippincott Williams & Wilkins, 2003: pp. 298-325.
19. Dummer JS,. Risk factors and approaches to infection in transplant recipients. In:, Mandell GL, Douglas RG, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 6th edn. New York: Elsevier/Churchill Livingstone, 2005: p. 2477.
20. Munoz MA, Andres A, Gallego R, et al., Mycophenolate mofetil immunosuppressive therapies increase the incidence of cytomegalovirus infection in renal transplantation. Transplant Proc 2002: 34: 97.
21. Iwaki Y, Starzl TE, Yagihashi A, et al., Replacement of donor lymphoid tissue in small-bowel transplants. Lancet 1991: 337: 818-819.
22. Roche JK, Cheung KS, Boldogh I, Huang ES, Lang DJ,. Cytomegalovirus: Detection in human colonic and circulating mononuclear cells in association with gastrointestinal disease. Int J Cancer 1981: 27: 659-667.
23. Manez R, Kusne S, Green M, et al., Incidence and risk factors associated with the development of cytomegalovirus disease after intestinal transplantation. Transplantation 1995: 59: 1010-1014.
24. Bonaros N, Mayer B, Schachner T, Laufer G, Kocher A,. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: A meta-analysis. Clin Transplant 2008: 22: 89-97.
25. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG,. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005: 143: 870-880.
26. Moreso F, Seron D, Morales JM, et al., Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses. Clin Transplant 1998: 12: 198-205.
27. Meier-Kriesche HU, Friedman G, Jacobs M, Mulgaonkar S, Vaghela M, Kaplan B,. Infectious complications in geriatric renal transplant patients: Comparison of two immunosuppressive protocols. Transplantation 1999: 68: 1496-1502.
28. Sarmiento JM, Munn SR, Paya CV, Velosa JA, Nguyen JH,. Is cytomegalovirus infection related to mycophenolate mofetil after kidney transplantation? A case-control study. Clin Transplant 1998: 12: 371-374.
29. Sarmiento JM, Dockrell DH, Schwab TR, Munn SR, Paya CV,. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients. Clin Transplant 2000: 14: 136-138.
30. Ter Meulen CG, Wetzels JF, Hilbrands LB,. The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation. Nephrol Dial Transplant 2000: 15: 711-714.
31. Giral M, Nguyen JM, Daguin P, et al., Mycophenolate mofetil does not modify the incidence of cytomegalovirus (CMV) disease after kidney transplantation but prevents CMV-induced chronic graft dysfunction. J Am Soc Nephrol 2001: 12: 1758-1763.
32. Bernabeu-Wittel M, Naranjo M, Cisneros JM, et al., Infections in renal transplant recipients receiving mycophenolate versus azathioprine-based immunosuppression. Eur J Clin Microbiol Infect Dis 2002: 21: 173-180.
33. Kuypers DR, Evenepoel P, Maes BD, Coosemans W, Pirenne J, Vanrenterghem YF,. Role of immunosuppressive drugs in the development of tissue-invasive cytomegalovirus infection in renal transplant recipients. Transplant Proc 2002: 34: 1164-1170.
34. De Maar EF, Verschuuren EA, Homan Vd Heide JJ, et al., Effects of changing immunosuppressive regimen on the incidence, duration, and viral load of cytomegalovirus infection in renal transplantation: A single center report. Transpl Infect Dis 2002: 4: 17-24.
35. Basic-Jukic N, Kes P, Bubic-Filipi LJ, Puretic Z, Brunetta B, Pasini J,. Does mycophenolate mofetil increase the incidence of cytomegalovirus disease compared with azathioprine after cadaveric kidney transplantation? Transplant Proc 2005: 37: 850-851.
36. Satoh S, Tada H, Murakami M, et al., The influence of mycophenolate mofetil versus azathioprine and mycophenolic acid pharmacokinetics on the incidence of acute rejection and infectious complications after renal transplantation. Transplant Proc 2005: 37: 1751-1753.
37. Fisher RA, Saggi BH, Ferreira-Gonzalez A, Wolfe L, Posner MP,. Prospective validation of quantitative polymerase chain reaction for management of cytomegalovirus disease in solid-organ transplant patients. Transplantation 2002: 74: 573-576.
38. Paterson DL, Singh N, Panebianco A, et al., Infectious complications occurring in liver transplant recipients receiving mycophenolate mofetil. Transplantation 1998: 66: 593-598.
39. Jain A, Orloff M, Kashyap R, et al., Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients? Transplant Proc 2005: 37: 3182-3186.
40. Valcyte (Valganciclovir HCL Tablets) Dear Healthcare Professional Letter Sep 2003 (letter from Roche Pharmaceuticals) [Internet]. Available at: (accessed July 13, 2011).
41. Kalil AC, Freifeld AG, Lyden ER, Stoner JA,. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: An evidence-based reassessment of safety and efficacy. PLoS ONE 2009: 4: e5512.
42. Lopez C, Simmons RL, Mauer SM, Park B, Najarian JS, Good RA,. Virus infections may trigger rejection in immunosuppressed renal transplant recipients. Proc Clin Dial Transplant Forum 1972: 2: 107-111.
43. Lopez C, Simmons RL, Mauer SM, Najarian JS, Good RA, Gentry S,. Association of renal allograft rejection with virus infections. Am J Med 1974: 56: 280-289.
44. Rubin RH,. The pathogenesis and clinical management of cytomegalovirus infection in the organ transplant recipient: The end of the 'silo hypothesis.' Curr Opin Infect Dis 2007: 20: 399-407.